Eric M. Ostertag, M.D., Ph.D.
Dr. Ostertag is currently Executive Chairman, after serving as our founding Chief Executive Officer from July 2015 to January 2022 and as a member of our board of directors since May 2015. Dr. Ostertag invented or co-invented a majority of the genetic engineering platform technologies used by Poseida for human therapeutics. In February 2015 he directed Poseida’s spin out from Transposagen Biopharmaceuticals, Inc., a biotechnology company that developed many of the genetic engineering platform technologies and continued to commercialize those technologies in several non-human therapeutic fields until a successful exit. Dr. Ostertag founded and served as Transposagen’s Chief Executive Officer and President for 13 years. He also founded Hera BioLabs to commercialize the animal model, cell line and research reagent applications and Demeetra AgBio to commercialize the bioprocessing and crop science applications of the genetic engineering platforms. Dr. Ostertag continues to serve as Chairman of the board of directors of both Hera and Demeetra. Previously, he co-founded and served as Chief Executive Officer and President of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the development of human therapeutics based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as Executive Vice President of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks. Dr. Ostertag received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison.